Health and Human Services Secretary Robert F. Kennedy Jr. announced the revocation of emergency use authorizations (EUAs) for COVID-19 vaccines, marking a significant shift in federal policy. RFK Jr. outlined four key objectives he claimed to have achieved: ensuring vaccine availability for vulnerable populations, demanding placebo-controlled trials from pharmaceutical companies, and securing full FDA approval for specific age groups.

The decision follows the Biden administration’s termination of the COVID-19 public health emergency on May 11, 2023. Under EUAs, medical products are authorized when no approved alternatives exist. The Pfizer and Moderna vaccines initially received EUAs before obtaining full FDA approval in 2021 and 2022, respectively. Full approval requires demonstrating safety and efficacy, whereas EUAs prioritize balancing potential benefits against risks.

The FDA recently granted full approval for Moderna’s vaccine for children aged 6 months to 11 years, making it the first such vaccine available without an EUA. However, critics argue the move leaves gaps in access, particularly for younger children. Dr. Susan Kressly of the American Academy of Pediatrics called the decision “deeply troubling,” warning of risks during respiratory virus season.

RFK Jr. replaced all 17 members of the CDC’s vaccine advisory committee with individuals skeptical of COVID-19 vaccines, raising concerns about future recommendations. While doctors can still prescribe vaccines off-label, this complicates access for patients relying on pharmacies. The final approval process will determine coverage by insurers, potentially limiting options for those ineligible for updated shots.